Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma.

Exp Hematol Oncol · 2018 · PMC6127913 · PMID 30202637

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, this trend did not reach statistical significance [ 18 ].

also in 111,027 other papers

showed a trendno p-value reported

In turn, Pazopanib in combination with another TKI drug Trametinib showed a trend to increase 4-month progression-free survival as compared with the prespecified null hypothesized 4-month PFS of 25%.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.